**Supplementary Material Contents**

Supplementary Table 1. Effect of change in CST on the change in BCVA in patients treated with IAI .............................................................................................................................................. 3

Supplementary Table 2. Correlation between CST and BCVA by treatment group in GALILEO trial ............................................................................................................................................. 4

Supplementary Fig. 1 Correlations between absolute CST and absolute BCVA in the sham/IAI group in COPERNICUS trial ....................................................................................................... 5

Supplementary Fig. 2 Correlations between absolute CST and absolute BCVA in the IAI group in COPERNICUS trial ................................................................................................................. 8

Supplementary Fig. 3 Correlations between changes in CST and changes in BCVA from baseline in the sham/IAI group in COPERNICUS trial ...............................................................11

Supplementary Fig. 4 Correlation between absolute CST and absolute BCVA in the sham/IAI group in GALILEO trial ..........................................................................................................................13

Supplementary Fig. 5 Correlation between absolute CST and absolute BCVA in the IAI group in GALILEO trial ..........................................................................................................................15

Supplementary Fig. 6 Correlations between changes in CST and changes in BCVA from baseline in the sham/IAI group in GALILEO trial ..............................................................................................18

Supplementary Fig. 7 Correlations between changes in CST and changes in BCVA from baseline in the IAI group in GALILEO trial ..............................................................................................20

Supplementary Fig. 8 Correlations between absolute CST and absolute BCVA in the Laser/IAI group in VIBRANT trial .................................................................................................................22

Supplementary Fig. 9 Correlations between absolute CST and absolute BCVA in the IAI group in VIBRANT trial ..........................................................................................................................24
Supplementary Fig. 10 Correlations between changes in CST and changes in BCVA in the Laser/IAI group in VIBRANT trial.
Supplementary Table 1. Effect of change in CST on the change in BCVA in patients treated with IAI

| Study   | Visit   | n   | Model Estimate | SE  | 95% CI    | r²  | P-value |
|---------|---------|-----|----------------|-----|-----------|-----|---------|
| COPERNICUS | Week 100 | 99  | 2.1            | 0.7 | (0.8, 3.5) | 21% | 0.003   |
| GALILEO | Week 76  | 87  | 2.4            | 0.5 | (1.3, 3.5) | 33% | <0.001  |
| VIBRANT | Week 52  | 54  | 2.2            | 1.2 | (-0.2, 4.5) | 23% | 0.07    |

BCVA, best-corrected visual acuity; CI, confidence interval; CST, central subfield thickness; IAI, intravitreal aflibercept injection; PRN, pro re nata; r, correlation; SE, standard error.
### Supplementary Table 2. Correlation between CST and BCVA by treatment group in GALILEO trial

| Visit    | Sham/IAI | IAI |
|----------|----------|-----|
|          | n        | r (95% CI) | P-value | n        | r (95% CI) | P-value |
| **Correlation between BCVA and CST** |          |       |       |          |       |       |
| Baseline | 68       | −0.22 (−0.43, 0.03) | 0.08 | 103      | −0.23 (−0.40, −0.04) | 0.02  |
| Week 12  | 62       | −0.40 (−0.59, −0.16) | 0.001| 96       | −0.07 (−0.26, 0.14)  | 0.52  |
| Week 24  | 55       | −0.62 (−0.76, −0.42) | <0.001| 97      | −0.04 (−0.24, 0.16)  | 0.70  |
| Week 52  | 50       | −0.55 (−0.71, −0.31) | <0.001| 89      | −0.13 (−0.33, 0.09)  | 0.24  |
| Week 76  | 50       | −0.11 (−0.38, 0.18)  | 0.45 | 87       | −0.52 (−0.66, −0.35) | <0.001|
| **Correlation between changes in BCVA and changes in CST** |          |       |       |          |       |       |
| Week 12  | 62       | −0.01 (−0.26, 0.24)  | 0.92 | 96       | −0.30 (−0.47, −0.11) | 0.003|
| Week 24  | 55       | −0.34 (−0.55, −0.08) | 0.01 | 97       | −0.23 (−0.41, −0.03) | 0.02  |
| Week 52  | 50       | −0.15 (−0.41, 0.14)  | 0.32 | 89       | −0.40 (−0.56, −0.20) | <0.001|
| Week 76  | 50       | 0.13 (−0.15, 0.40)   | 0.35 | 87       | −0.45 (−0.60, −0.26) | <0.001|

In GALILEO, study participants with macular edema secondary to CRVO received IAI 2q4 or sham injections every four weeks through week 24, for a total of six doses. From weeks 24 to 48, study participants in the IAI 2q4 group received IAI PRN based on prespecified re-treatment criteria. Study participants in the sham group continued to receive sham through week 48. From week 52 to week 76, study participants in both groups received IAI PRN. 2q4, 2 mg every 4 weeks; 2q8, 2 mg every 8 weeks; BCVA, best-corrected visual acuity; CI, confidence interval; CST, central subfield thickness; IAI, intravitreal aflibercept injection; PRN, pro re nata; r, correlation.
Supplementary Fig. 1 Correlations between absolute CST and absolute BCVA in the sham/IAI group in COPERNICUS trial
Solid lines indicate the correlation line, and dashed lines indicate the 95% CIs. In COPERNICUS, study participants with macular edema secondary to CRVO received IAI 2q4 or sham injections every four weeks through week 24, for a total of six doses. From weeks 24 to 100, all study participants received IAI pro re nata (PRN) based on prespecified re-treatment criteria. 2q4, 2 mg every 4 weeks; BCVA, best-corrected visual acuity; CI, confidence interval; CST, central subfield thickness; IAI, intravitreal aflibercept injection; PRN, pro re nata; r, correlation.
**Supplementary Fig. 2** Correlations between absolute CST and absolute BCVA in the IAI group in COPERNICUS trial
Solid lines indicate the correlation line, and dashed lines indicate the 95% CIs. In COPERNICUS, study participants with macular edema secondary to CRVO received IAI 2q4 or sham injections every four weeks through week 24, for a total of six doses. From weeks 24 to 100, all study participants received IAI pro re nata (PRN) based on prespecified re-treatment criteria. 2q4, 2 mg every 4 weeks; BCVA, best-corrected visual acuity; CI, confidence interval; CST, central subfield thickness; IAI, intravitreal aflibercept injection; PRN, pro re nata; r, correlation.
**Supplementary Fig. 3** Correlations between changes in CST and changes in BCVA from baseline in the sham/IAI group in COPERNICUS trial

Solid lines indicate the correlation line, and dashed lines indicate the 95% CIs. In COPERNICUS, study participants with macular edema secondary to CRVO received IAI 2q4 or...
sham injections every four weeks through week 24, for a total of six doses. From weeks 24 to 100, all study participants received IAI pro re nata (PRN) based on prespecified re-treatment criteria. 2q4, 2 mg every 4 weeks; BCVA, best-corrected visual acuity; CI, confidence interval; CST, central subfield thickness; IAI, intravitreal aflibercept injection; PRN, pro re nata; r, correlation; $R^2$, coefficient of determination.
Supplementary Fig. 4 Correlation between absolute CST and absolute BCVA in the sham/IAI group in GALILEO trial

Solid lines indicate the correlation line, and dashed lines indicate the 95% CIs. In GALILEO, study participants with macular edema secondary to CRVO received IAI 2q4 or sham injections.
every four weeks through week 24, for a total of six doses. From weeks 24 to 48, study participants in the IAI 2q4 group received IAI PRN based on prespecified re-treatment criteria. Study participants in the sham group continued to receive sham through week 48. From week 52 to week 76, study participants in both groups received IAI PRN. 2q4, 2 mg every 4 weeks; 2q8, 2 mg every 8 weeks; BCVA, best-corrected visual acuity; CI, confidence interval; CST, central subfield thickness; IAI, intravitreal aflibercept injection; PRN, pro re nata; r, correlation.
Supplementary Fig. 5 Correlation between absolute CST and absolute BCVA in the IAI group in GALILEO trial
Solid lines indicate the correlation line, and dashed lines indicate the 95% CIs. In GALILEO, study participants with macular edema secondary to CRVO received IAI 2q4 or sham injections every four weeks through week 24, for a total of six doses. From weeks 24 to 48, study participants in the IAI 2q4 group received IAI PRN based on prespecified re-treatment criteria. Study participants in the sham group continued to receive sham through week 48. From week 52 to week 76, study participants in both groups received IAI PRN. 2q4, 2 mg every 4 weeks; 2q8, 2 mg every 8 weeks; BCVA, best-corrected visual acuity; CI, confidence interval; CST, central subfield thickness; IAI, intravitreal aflibercept injection; PRN, pro re nata; r, correlation.
Supplementary Fig. 6 Correlations between changes in CST and changes in BCVA from baseline in the sham/IAI group in GALILEO trial

Solid lines indicate the correlation line, and dashed lines indicate the 95% CIs. In GALILEO, study participants with macular edema secondary to CRVO received IAI 2q4 or sham injections.
every four weeks through week 24, for a total of six doses. From weeks 24 to 48, study participants in the IAI 2q4 group received IAI PRN based on prespecified re-treatment criteria. Study participants in the sham group continued to receive sham through week 48. From week 52 to week 76, study participants in both groups received IAI PRN. 2q4, 2 mg every 4 weeks; 2q8, 2 mg every 8 weeks; BCVA, best-corrected visual acuity; CI, confidence interval; CST, central subfield thickness; IAI, intravitreal aflibercept injection; PRN, pro re nata; r, correlation; $R^2$, coefficient of determination.
Supplementary Fig. 7 Correlations between changes in CST and changes in BCVA from baseline in the IAI group in GALILEO trial

Solid lines indicate the correlation line, and dashed lines indicate the 95% CIs. In GALILEO, study participants with macular edema secondary to CRVO received IAI 2q4 or sham injections.
every four weeks through week 24, for a total of six doses. From weeks 24 to 48, study participants in the IAI 2q4 group received IAI PRN based on prespecified re-treatment criteria. Study participants in the sham group continued to receive sham through week 48. From week 52 to week 76, study participants in both groups received IAI PRN. 2q4, 2 mg every 4 weeks; 2q8, 2 mg every 8 weeks; BCVA, best-corrected visual acuity; CI, confidence interval; CST, central subfield thickness; IAI, intravitreal aflibercept injection; PRN, pro re nata; r, correlation; R^2, coefficient of determination.
Supplementary Fig. 8 Correlations between absolute CST and absolute BCVA in the Laser/IAI group in VIBRANT trial

Solid lines indicate the correlation line, and dashed lines indicate the 95% CIs. In VIBRANT, study participants with macular edema secondary to BRVO received either laser at baseline or
IAI 2q4 from baseline through week 24. Both treatment groups received IAI 2q8 from week 24 through week 52. 2q4, 2 mg every 4 weeks; 2q8, 2 mg every 8 weeks; BCVA, best-corrected visual acuity; CI, confidence interval; CST, central subfield thickness; IAI, intravitreal aflibercept injection;
r, correlation.
Supplementary Fig. 9 Correlations between absolute CST and absolute BCVA in the IAI group in VIBRANT trial

Solid lines indicate the correlation line, and dashed lines indicate the 95% CIs. In VIBRANT, study participants with macular edema secondary to BRVO received either laser at baseline or
IAI 2q4 from baseline through week 24. Both treatment groups received IAI 2q8 from week 24 through week 52. 2q4, 2 mg every 4 weeks; 2q8, 2 mg every 8 weeks; BCVA, best-corrected visual acuity; CI, confidence interval; CST, central subfield thickness; IAI, intravitreal aflibercept injection;
r, correlation.
Supplementary Fig. 10 Correlations between changes in CST and changes in BCVA in the Laser/IAI group in VIBRANT trial

Solid lines indicate the correlation line, and dashed lines indicate the 95% CIs. In VIBRANT, study participants with macular edema secondary to BRVO received either laser at baseline or IAI 2q4 from baseline through week 24. Both treatment groups received IAI 2q8 from week 24 through week 52. 2q4, 2 mg every 4 weeks; 2q8, 2 mg every 8 weeks; BCVA, best-corrected visual acuity; CI, confidence interval; CST, central subfield thickness; IAI, intravitreal aflibercept injection; r, correlation; $R^2$, coefficient of determination.